ai3Bio
Therapeutics that target disease-causing T cells in autoimmunity
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
ai3Bio develops therapies aimed at resetting the immune system by targeting pathogenic T cells rather than broadly suppressing immunity. Its approach includes an LNP/mRNA platform and an antibody platform designed to clear disease-causing T cells. The company announced a $48 million Series A at launch in September 2026.
- Website
- ai3.bio
- Stage
- series-a
- Added via
- web
- Ownership
- unclaimed